Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma

Nature Communications

Volumn 6, Issue , 2015, Pages

  Nie, Zilin ^a   Du, Ming Qing ^b   McAllister Lucas, Linda M ^c   Lucas, Peter C ^c   Bailey, Nathanael G ^a   Hogaboam, Cory M ^a   Lim, Megan S ^a   Elenitoba Johnson, Kojo S J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

API2 PROTEIN; CASPASE; LIM DOMAIN AND ACTIN BINDING PROTEIN 1; MALT1 PROTEIN; PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; API2-MALT1 FUSION PROTEIN, HUMAN; CYTOSKELETON PROTEIN; LIMA1 PROTEIN, HUMAN; ONCOPROTEIN; SMALL INTERFERING RNA;

ANTIBIOTIC RESISTANCE; CANCER; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNE SYSTEM; PROTEIN; TUMOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CARCINOGENESIS; ENZYME MECHANISM; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MARGINAL ZONE LYMPHOMA; ONCOGENE; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; TANDEM MASS SPECTROMETRY; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENETICS; HEK293 CELL LINE; MASS SPECTROMETRY; METABOLISM; PATHOPHYSIOLOGY; PLASMID; SITE DIRECTED MUTAGENESIS;

CARCINOGENESIS; CYTOSKELETAL PROTEINS; HEK293 CELLS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MASS SPECTROMETRY; MICROSCOPY, FLUORESCENCE; MUTAGENESIS, SITE-DIRECTED; ONCOGENE PROTEINS, FUSION; PLASMIDS; PROTEOLYSIS; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 84928125250     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6908     Document Type: Article

References (70)

1. Akagi, T. et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18, 5785-5794 (1999).
2. Uren, A. G. et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell 6, 961-967 (2000).
3. Thome, M. Multifunctional roles for MALT1 in T-cell activation. Nat. Rev. Immunol. 8, 495-500 (2008).
4. Coornaert, B. et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 9, 263-271 (2008).
5. McAllister-Lucas, L. M. & Lucas, P. C. Finally, MALT1 is a protease! Nat. Immunol. 9, 231-233 (2008).
6. Rebeaud, F. et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 9, 272-281 (2008).
7. Qiao, Q. et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Mol. Cell 51, 766-779 (2013).
8. Ferch, U. et al. MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. Nat. Immunol. 8, 984-991 (2007).
9. Lucas, P. C. et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway. J. Biol. Chem. 276, 19012-19019 (2001).
10. Hachmann, J. et al. Mechanism and specificity of the human paracaspase MALT1. Biochem. J. 443, 287-295 (2012).
11. Wiesmann, C. et al. Structural determinants of MALT1 protease activity. J. Mol. Biol. 419, 4-21 (2012).
12. Yu, J. W., Jeffrey, P. D., Ha, J. Y., Yang, X. & Shi, Y. Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region. Proc. Natl Acad. Sci. USA 108, 21004-21009 (2011).
13. Hailfinger, S. et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc. Natl Acad. Sci. USA 108, 14596-14601 (2011).
14. Staal, J. et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 30, 1742-1752 (2011).
15. Uehata, T. et al. Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation. Cell 153, 1036-1049 (2013).
16. Rosebeck, S., Rehman, A. O., Lucas, P. C. & McAllister-Lucas, L. M. From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle 10, 2485-2496 (2011).
17. Ruefli-Brasse, A. A., French, D. M. & Dixit, V. M. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 302, 1581-1584 (2003).
18. Vicente-Duenas, C. et al. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc. Natl Acad. Sci. USA 109, 10534-10539 (2012).
19. Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
20. Ferch, U. et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 206, 2313-2320 (2009).
21. Nagel, D. et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 22, 825-837 (2012).
22. Fontan, L. et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 22, 812-824 (2012).
23. Isaacson, P. G. & Du, M. Q. MALT lymphoma: from morphology to molecules. Nat. Rev. Cancer 4, 644-653 (2004).
24. Liu, H. et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357, 39-40 (2001).
25. Morgan, J. A. et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res. 59, 6205-6213 (1999).
26. Dierlamm, J. et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601-3609 (1999).
27. Sugiyama, T. et al. API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 120, 1884-1885 (2001).
28. Motegi, M. et al. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am. J. Pathol. 156, 807-812 (2000).
29. Nakamura, T. et al. Clinicopathologic comparison between the API2-MALT1 chimeric transcript-positive and -negative gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J. Cancer Res. 93, 677-684 (2002).
30. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3, 401-410 (2002).
31. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9, 459-470 (2002).
32. Vandenabeele, P. & Bertrand, M. J. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat. Rev. Immunol. 12, 833-844 (2012).
33. Gyrd-Hansen, M. & Meier, P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10, 561-574 (2010).
34. Zhou, H., Du, M. Q. & Dixit, V. M. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7, 425-431 (2005).
35. Hosokawa, Y., Suzuki, H., Suzuki, Y., Takahashi, R. & Seto, M. Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma. Cancer Res. 64, 3452-3457 (2004).
36. LaCasse, E. C. et al. IAP-targeted therapies for cancer. Oncogene 27, 6252-6275 (2008).
37. Rosebeck, S. et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 331, 468-472 (2011).
38. Abe, K. & Takeichi, M. EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc. Natl Acad. Sci. USA 105, 13-19 (2008).
39. Chai, J. et al. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406, 855-862 (2000).
40. Maul, R. S. & Chang, D. D. EPLIN, epithelial protein lost in neoplasm. Oncogene 18, 7838-7841 (1999).
41. Anastasov, N. et al. Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J. Hematopathol. 2, 9-19 (2009).
42. Jiang, W. G. et al. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol. Cancer 7, 71 (2008).
43. Zhang, S. et al. Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transition. J. Biol. Chem. 288, 1469-1479 (2013).
44. Liu, Y., Sanders, A. J., Zhang, L. & Jiang, W. G. EPLIN-alpha expression in human oesophageal cancer and its impact on cellular aggressiveness and clinical outcome. Anticancer Res. 32, 1283-1289 (2012).
45. Hailfinger, S. et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 106, 19946-19951 (2009).
46. Boehm, T., Foroni, L., Kaneko, Y., Perutz, M. F. & Rabbitts, T. H. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl Acad. Sci. USA 88, 4367-4371 (1991).
47. McGuire, E. A. et al. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol. Cell. Biol. 9, 2124-2132 (1989).
48. Boehm, T. et al. The mechanism of chromosomal translocation t(11;14) involving the T-cell receptor C delta locus on human chromosome 14q11 and a transcribed region of chromosome 11p15. EMBO J. 7, 385-394 (1988).
49. McGuire, E. A., Rintoul, C. E., Sclar, G. M. & Korsmeyer, S. J. Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma. Mol. Cell. Biol. 12, 4186-4196 (1992).
50. Fisch, P. et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 7, 2389-2397 (1992).
51. Royer-Pokora, B., Loos, U. & Ludwig, W. D. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene 6, 1887-1893 (1991).
52. Garcia, I. S. et al. A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia. Oncogene 6, 577-582 (1991).
53. Wang, K. et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469, 216-220 (2011).
54. Van Vlierberghe, P. et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood 108, 3520-3529 (2006).
55. McCormack, M. P., Forster, A., Drynan, L., Pannell, R. & Rabbitts, T. H. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol. Cell. Biol. 23, 9003-9013 (2003).
56. McCormack, M. P. et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 327, 879-883 (2010).
57. Sanchez-Izquierdo, D. et al. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood 101, 4539-4546 (2003).
58. Song, Y., Maul, R. S., Gerbin, C. S. & Chang, D. D. Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol. Biol. Cell 13, 1408-1416 (2002).
59. Leitner, L., Shaposhnikov, D., Descot, A., Hoffmann, R. & Posern, G. Epithelial Protein Lost in Neoplasm alpha (Eplin-alpha) is transcriptionally regulated by G-actin and MAL/MRTF coactivators. Mol. Cancer 9, 60 (2010).
60. Bernheim, A. et al. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab. Invest. 88, 464-473 (2008).
61. Zheng, Q. & Zhao, Y. The diverse biofunctions of LIM domain proteins: determined by subcellular localization and protein-protein interaction. Biol. Cell 99, 489-502 (2007).
62. Kang, S. et al. PCD1, a novel gene containing PDZ and LIM domains, is overexpressed in several human cancers. Cancer Res. 60, 5296-5302 (2000).
63. Sanchez-Garcia, I. & Rabbitts, T. H. The LIM domain: a new structural motif found in zinc-finger-like proteins. Trends Genet. 10, 315-320 (1994).
64. Schmeichel, K. L. & Beckerle, M. C. The LIM domain is a modular protein-binding interface. Cell 79, 211-219 (1994).
65. Matthews, J. M., Lester, K., Joseph, S. & Curtis, D. J. LIM-domain-only proteins in cancer. Nat. Rev. Cancer 13, 111-122 (2013).
66. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
67. Busino, L. et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a prosurvival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375-385 (2012).
68. Theil, J. et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 97, 3191-3196 (2001).
69. McDonnell, S. R. et al. NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis. Oncogene 31, 3733-3740 (2012).
70. McDonnell, S. R. et al. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. Blood 122, 958-968 (2013).